Vetter's New Commercial Line Validated for cGMP Filling - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter's New Commercial Line Validated for cGMP Filling


RELATED ARTICLES

More in GMPs/Validation

A new filling line at Vetter's Ravensburg Vetter South facility is fully validated and ready for cGMP filling after successful media-fill completion, with a customer project underway, the company announced in a press release. The line's capacity ranges from mid- to large-volume batch sizes, with a maximum filling speed of 800 presterilized syringes per minute. The line currently fills 1-mL, standard-format syringes, and additional formats will be added in the future.

The line was designed to exceed cGMP requirements. It uses Restricted Access Barrier Systems (RABS) and fully automated transfer of sterile, packed tubs throughout the filling process to minimize human contact. Novel disinfection techniques include a spray disinfection tunnel for bagged tubs that was codeveloped by Vetter and the equipment manufacturer.

The line also includes an end-to-end track-and-trace system that features automated disposal of rejects and sample removal following the filling process. Fully automated, in-line control of syringe closures uses a three-dimensional scanner prior to filling to minimize API loss and reduce risk of contamination. An in-line, automatic weighing system monitors filling quantities.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here